Startup targets orphan kidney disease with former Merck drug

cafead

Administrator
Staff member
  • cafead   Jan 26, 2021 at 11:12: AM
via Vera Therapeutics licensed the drug candidate after analysis of earlier trials revealed its promise. Boosted by $80 million in Series C funding, the company hopes to launch a phase 2B trial this year.

article source